Immix biopharma to present abstract at the upcoming ash 2025 annual meeting

Los angeles, ca, oct. 06, 2025 (globe newswire) -- immix biopharma, inc. (“immixbio”, “company”, “we” or “us” or ”immx”), the global leader in relapsed/refractory al amyloidosis, today announced that it will present a nxc-201 abstract at the upcoming american society of hematology (ash) 67th annual meeting and exposition to be held december 6-9, 2025, in orlando, florida.
ASH Ratings Summary
ASH Quant Ranking